Artificial Intelligence and Novel Trial Designs for Acute Ischemic Stroke: Opportunities and Challenges

作者：Joseph P. Broderick, Eva Mistry, Paul Wechsler, Mitchell S.V. Elkind, David S. Liebeskind, George Harston, Jake Wolenberg, Jennifer Frontera, W. Taylor Kimberly, Christopher G. Favilla, Johannes Boltze, Johanna M. Ospel, Edgar A. Samaniego, Opeolu Adeoye, Scott E. Kasner, Lee H. Schwamm, Gregory W. Albers, Óscar Bolaños, Bruce Campbell, Davide Carone, Emir Deljkich, Ali Eltatawy, Marc Fisher, Jeremy J. Heit, Michael D. Hill, Gary Houser, Edward C. Jauch, Hooman Kamel, Del Kjos, Sara Ortiz-Toquero, Sean I. Savitz, Kevin N. Sheth, Michael Tymianski, Ajay K. Wakhloo · 发表于：Stroke · 年份：2025 · DOI：10.1161/strokeaha.125.052146 · 被引用次数：5 · 研究领域：Acute Ischemic Stroke Management、Artificial Intelligence in Healthcare and Education、Stroke Rehabilitation and Recovery

The Stroke Treatment Academic Industry Roundtable convened a workshop regarding artificial intelligence (AI) and innovative clinical trial designs during the Stroke Treatment Academic Industry Roundtable XIII meeting on March 28, 2025. This forum brought together stroke physicians and researchers, and industry representatives to discuss the current use and future opportunities for AI and novel trial designs in acute stroke trials. AI already plays a substantial role in the treatment of acute stroke with regards to imaging but is poised to have a much larger impact in clinical care and research trials over the coming years. The quality and understanding of the data are used to train the AI, the human element needed to ensure training is successful, and the clinician and trialist at the bedside, the humans "in the loop," will be necessary to maximize AI's effectiveness in clinical practice and trials. Platform trials address multiple scientific questions in an area of medicine simultaneously within the same trial structure by sharing controls across multiple interventions. While platform trials increase efficiency and potentially decrease the time needed to answer important clinical scientific questions, they also can introduce complexity to standard workflows. Future acute ischemic stroke clinical trials should incorporate elements of pragmatic and patient-centered trial design when possible. Pragmatic trials aim to assess the effectiveness of treatments when they are implemen...